Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
A treat-to-target strategy that aims for a serum urate level below 0.36 mmol/L leads to better gout remission than symptom-driven care, which relies on starting treatment only…
Antioxidant strategies may help male infertility in aging men with immune disorders by reducing oxidative stress, but evidence is preliminary and personalized approaches are…
Anti-tissue transglutaminase (tTG) IgA and anti-endomysial antibody (EMA) IgA show high concordance for detecting celiac disease autoantibodies, with studies reporting 95-100%…
AI helps diagnose bladder, prostate, and kidney cancers by combining imaging, pathology, and genetic data for more accurate detection and risk assessment.
Fluoroquinolone prophylaxis reduces febrile neutropenia (fever with low white blood cells) in children with ALL, but it is not a treatment for high fevers; it is a preventive…
Yes, CPX-351 improves survival in patients with AML and myelodysplasia-related changes compared to standard chemotherapy, especially in those with AML-MR subtype.
Yes, a case report describes a 68-year-old woman with myeloid sarcoma relapse in the breast 6 years after initial nasal cavity presentation.
Yes, Xpovio (selinexor) in combination with dexamethasone alone is FDA-approved for heavily pretreated relapsed/refractory multiple myeloma after at least four prior therapies.
Yes, natural products like lactacystin, salinosporamide A, and polyphenols can target the proteasome, but none are approved treatments for multiple myeloma; marizomib, a natural…
Yes, Revlimid (lenalidomide) is FDA-approved as maintenance therapy after autologous stem cell transplant for multiple myeloma.
Yes, Pomalyst is FDA-approved for both multiple myeloma and Kaposi sarcoma, including AIDS-related and HIV-negative cases.
The case report used a combination of ixazomib, lisaftoclax, and dexamethasone (ILD) as maintenance therapy after CAR-T cell therapy for ultra-high-risk relapsed multiple myeloma.
Yes, hematologists recommend using tocilizumab to manage cytokine release syndrome (CRS) caused by bispecific antibodies in relapsed/refractory multiple myeloma, including…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.